 Moderna stock jumped late Tuesday after the company said its experimental RSV vaccine proved nearly 84 effective in older adults. The post Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up appeared first on Investors Business Daily. 